Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzuloparib + apatinib maintenance for stable ovarian cancer after chemotherapy
ChiCTR2300076678Phase 2Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital
- Start
- Jul 2023
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and Rivoceranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Hospital. Primary endpoint: Median progression-free survival. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2300076678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076678.